Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset

Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings..

Medienart:

E-Artikel

Erscheinungsjahr:

2017

Erschienen:

2017

Enthalten in:

Zur Gesamtaufnahme - volume:215

Sprache:

Englisch

Beteiligte Personen:

Chen, Zhe [VerfasserIn]
Bao, Linlin [VerfasserIn]
Chen, Cong [VerfasserIn]
Zou, Tingting [VerfasserIn]
Xue, Ying [VerfasserIn]
Li, Fengdi [VerfasserIn]
Lv, Qi [VerfasserIn]
Gu, Songzhi [VerfasserIn]
Gao, Xiaopan [VerfasserIn]
Cui, Sheng [VerfasserIn]
Wang, Jianmin [VerfasserIn]
Qin, Chuan [VerfasserIn]
Jin, Qi [VerfasserIn]

Links:

Volltext

Themen:

Research-article

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

JST134575679